Quantcast

Latest Cancer treatments Stories

2014-05-15 23:00:47

Created by Society for Immunotherapy of Cancer, this video was created to raise awareness about the excitement and the hope cancer immunotherapy clinical trials can offer patients with NSCLC today. Milwaukee, WI (PRWEB) May 15, 2014 A recently released video on cancer immunotherapy is offering new hope to patients with non-small cell lung cancer (NSCLC), the type of cancer which makes up 85% to 90% of all lung cancer cases in the US and claims more lives each year than colon, breast, and...

2014-05-15 08:32:30

First Case Study Announced While Broader Data Being Collected; Evidence Indicates Substantial Tumor Necrosis and Initial Tumor Regression BETHESDA, Md., May 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an initial patient case study, showing signs of tumor necrosis (tumor death) and initial tumor regression, from the Company's ongoing...

2014-05-14 20:23:42

Data underscore breadth of oncology portfolio WOODCLIFF LAKE, N.J., May 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2014. "Anchored by our human health care mission, Eisai's commitment to cancer patients and their families is evidenced by our focus on sometimes overlooked patient...

2014-05-14 08:30:35

Two new clinical utility studies of Decipher published in BJU International and Current Medical Research and Opinion SAN DIEGO, May 14, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced data from two new clinical utility studies demonstrating that Decipher® Prostate Cancer Classifier significantly changed treatment decisions and increased confidence in treatment decision-making for men considering adjuvant therapy following prostate surgery. The studies are being published...

2014-05-09 19:06:35

Massachusetts Institute of Technology Nanoparticles that stagger delivery of 2 drugs knock out aggressive tumors in mice MIT researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage. In studies with mice, the research team showed that this one-two punch, which relies on a nanoparticle that carries two drugs and releases them at different times, dramatically shrinks lung and breast...

2014-05-06 23:01:41

Retrospective Study of Roswell Park Patients Documents Safety and Benefit of Complex Immunotherapy Buffalo, NY (PRWEB) May 06, 2014 A retrospective study published online ahead of print in the medical journal Urology by a physician team from Roswell Park Cancer Institute (RPCI) found that patients with metastatic kidney cancer — even those with chronic renal insufficiency — can tolerate and benefit from a treatment called high-dose interleukin-2 (HDIL-2) immunotherapy. Patients with...

2014-05-05 08:29:46

SAN DIEGO, May 5, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin(®) (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers. The open-label study is expected to enroll up to 64...

2014-05-05 08:28:31

New Data Include Results on Oncotype DX's Prognosis of Late Recurrence in Invasive Breast Cancer and Clinical Utility in Ductal Carcinoma In Situ (DCIS) REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX(®) in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place...

2014-05-02 08:25:16

Large Study Published in The Oncologist Underscores Test's Value in Guiding Treatment Decisions REDWOOD CITY, Calif., May 2, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that The Oncologist published positive results from an Oncotype DX(®) colon cancer decision impact study, demonstrating that Recurrence Score(®) results changed treatment recommendations in 45 percent of stage II colon cancer patients. The study was conducted in collaboration with the...

Protein Discovery Could Boost Efficacy Of Bone Marrow Replacement Treatments
2014-05-01 03:38:51

University of California - San Diego Researchers at the University of California, San Diego School of Medicine report that a protein called beta-catenin plays a critical, and previously unappreciated, role in promoting recovery of stricken hematopoietic stem cells after radiation exposure. The findings, published in the May 1 issue of Genes and Development, provide a new understanding of how radiation impacts cellular and molecular processes, but perhaps more importantly, they suggest...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.